TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10598700

Group type: COMPARATOR
Intervention: Standard valve, siphon-reducing valve (Delta), flow-limiting valve (Orbis Sigma)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Frontal horn catheter tip location
Number of subjects: 344

Group type: COMPARATOR
Intervention: Occipital horn catheter tip location
Number of subjects: 344

Group type: COMPARATOR
Intervention: Ventricular catheter tips surrounded by cerebrospinal fluid
Number of subjects: 344

Group type: COMPARATOR
Intervention: Ventricular catheter tips touching the brain
Number of subjects: 344

Group type: COMPARATOR
Intervention: Patients with myelomeningocele
Number of subjects: 344

Group type: COMPARATOR
Intervention: Patients with large ventricles
Number of subjects: 344
Study: 8550958

Group type: EXPERIMENTAL
Intervention: CAMDEX diagnostic interview
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: CAMDEX criteria
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Diagnostic interview
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Diagnostic criteria for major depressive disorder
Number of subjects: 1173
Study: 1743317

Group type: EXPERIMENTAL
Intervention: 0.1‐mg Estraderm Patch worn for 7 days with 0.6 mL of ethanol injected on day 3
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.1‐mg Estraderm Patch worn for 7 days without ethanol
Number of subjects: 8
Study: 6292957

Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin ophthalmic solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chloramphenicol ophthalmic solution
Number of subjects: 40
Study: 31928864

Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS (10Hz, 250 pulse) - single treatment
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS - daily for 3 days, twice-daily for 5 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham stimulation - twice-daily for 5 days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS
Number of subjects: 72
Study: 31881852

Group type: EXPERIMENTAL
Intervention: Omega-3 supplements
Number of subjects: 299

Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Healthy diet
Number of subjects: 299
Study: 28626140

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (docosahexaenoic acid (DHA) 300 mg/day, eicosapentaenoic acid (EPA) 100 mg/day, arachidonic acid (ARA) 120 mg/day)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 113
Study: 27150344

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS) for cup placement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional technique for cup placement (Control)
Number of subjects: 60
Study: 25103718

Group type: EXPERIMENTAL
Intervention: Group metacognitive training (MCT) targeting cognitive biases
Number of subjects: 150

Group type: COMPARATOR
Intervention: Neuropsychological training (COGPACK)
Number of subjects: 150
Study: 22038497

Group type: EXPERIMENTAL
Intervention: Tart cherry juice concentrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18710719

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (folic acid tablets)
Number of subjects: 30
Study: 17140552

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 1200
Study: 15985034

Group type: EXPERIMENTAL
Intervention: 4% hydroquinone cream (group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 4% hydroquinone, 0.05% tretinoin and 0.05% dexamethasone cream (group B)
Number of subjects: 64
Study: 11928798

Group type: EXPERIMENTAL
Intervention: Combined modality therapy for rectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less radical surgery
Number of subjects: 0
Study: 10096615

Group type: EXPERIMENTAL
Intervention: Chromos 694 Depilation Ruby Laser
Number of subjects: 36
Study: 8526599

Group type: EXPERIMENTAL
Intervention: Group A (rapid cooling at 4-5 degrees C)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Group B (slow cooling starting at 18 degrees C)
Number of subjects: 39
Study: 2187603

Group type: EXPERIMENTAL
Intervention: Solution A (168 mmol/L sugar, 326 mosm/kg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Solution D (90 mmol/L sugar, 240 mosm/kg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (A and D)
Number of subjects: 49
Study: 6103680

Group type: EXPERIMENTAL
Intervention: Timolol maleate 10 to 30 mg per day
Number of subjects: 20
Study: 31236874

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Baseline BMI
Number of subjects: 61

Group type: COMPARATOR
Intervention: Younger age
Number of subjects: 61

Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment-related increases in dietary restraint behaviors
Number of subjects: 61
Study: 27751654

Group type: EXPERIMENTAL
Intervention: CHR patients
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (GEMCAS)
Number of subjects: 144
Study: 26003406

Group type: EXPERIMENTAL
Intervention: Exercise program (aerobics, strength and flexibility training), three sessions a week for 16 weeks.
Number of subjects: 639

Group type: COMPARATOR
Intervention: Usual daily activities (control group).
Number of subjects: 639
Study: 23511304

Group type: EXPERIMENTAL
Intervention: Incompleteness induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 21135204

Group type: COMPARATOR
Intervention: 10 bp deletion polymorphism in GLUT1 gene
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: New variants in GLUT1 gene (c.972+17t>a and c.1016T>C)
Number of subjects: 96
Study: 19174530

Group type: EXPERIMENTAL
Intervention: GR genotypes (N363S, BclI, R23K)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: LC-MS/MS steroid measurements
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: BclI variant
Number of subjects: 1000
Study: 17369118

Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (original regimen)
Number of subjects: 43
Study: 15055028

Group type: EXPERIMENTAL
Intervention: Human Fibrin Glue (HFG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no Human Fibrin Glue)
Number of subjects: 50
Study: 10978856

Group type: EXPERIMENTAL
Intervention: Low-residual enteral formula (Osmolite HN)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-fat enteral formula (Pulmocare)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Glutamine-containing enteral formula (AlitraQ)
Number of subjects: 80

Group type: COMPARATOR
Intervention: NPO for 1 week (Control group)
Number of subjects: 80
Study: 8775569

Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 8
Study: 1343610

Group type: EXPERIMENTAL
Intervention: Liberal use of episiotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restricted use of episiotomy
Number of subjects: 0
Study: 6148879

Group type: EXPERIMENTAL
Intervention: Propranolol, 40 mg every 6 hours for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nadolol, 80 mg each morning for 14 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol and Nadolol
Number of subjects: 20
Study: 3722318

Group type: EXPERIMENTAL
Intervention: Radiotherapy for acute postpartum mastitis
Number of subjects: 606

Group type: COMPARATOR
Intervention: Non-irradiated women with acute postpartum mastitis
Number of subjects: 606
Study: 31609300

Group type: EXPERIMENTAL
Intervention: Interval training (INT) - alternating 3‐min intervals at 90% and 50% HRpeak
Number of subjects: 18

Group type: COMPARATOR
Intervention: Continuous training (CONT) - 70% HRpeak
Number of subjects: 18
Study: 29389542

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study: 27146108

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Crinone 8% vaginal gel, 90 mg per day) for 14 days in CC/IUI cycles
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Crinone 8% vaginal gel, 90 mg per day) for 14 days in Gn/IUI cycles
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (CC/IUI cycles without luteal-phase support)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (Gn/IUI cycles without luteal-phase support)
Number of subjects: 200
Study: 24244406

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy (ICBT) for 10 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Group cognitive behaviour therapy (GCBT) for 10 weeks
Number of subjects: 104
Study: 20507375

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (FM-SRP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Multiple session scaling and root planing (MS-SRP)
Number of subjects: 39
Study: 18405149

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion added to routine treatment, once daily for 10 days.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine therapeutic method without any method for preventing nosocomial infection (Control group).
Number of subjects: 100
Study: 16870951

Group type: EXPERIMENTAL
Intervention: α-adrenergic antagonists
Number of subjects: 734
Study: 12573204

Group type: EXPERIMENTAL
Intervention: OM-85 BV (3.5 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: OM-85 BV
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10894316

Group type: EXPERIMENTAL
Intervention: CIND diagnosis
Number of subjects: 3425

Group type: EXPERIMENTAL
Intervention: Age, stroke, heart failure
Number of subjects: 3425

Group type: EXPERIMENTAL
Intervention: Education, smoking
Number of subjects: 3425

Group type: EXPERIMENTAL
Intervention: CIND
Number of subjects: 3425
Study: 8852304

Group type: EXPERIMENTAL
Intervention: Greenspan's original model of personal competence
Number of subjects: 323

Group type: COMPARATOR
Intervention: AAMR model including adaptive skills
Number of subjects: 323
Study: 1736694

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 400 micrograms bolus followed by 40 micrograms/h infusion
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 800 micrograms bolus followed by 40 micrograms/h infusion
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 800 micrograms bolus after 2-chloroprocaine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 400 micrograms bolus after 2-chloroprocaine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (both doses) after bupivacaine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Epidural clonidine after bupivacaine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Epidural saline (control)
Number of subjects: 63
Study: 6736662

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Number of subjects: 150

Group type: COMPARATOR
Intervention: 10% povidone-iodine (1% free iodine)
Number of subjects: 150
Study: 31085043

Group type: EXPERIMENTAL
Intervention: Osimertinib and Bevacizumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined treatment (Osimertinib + Bevacizumab)
Number of subjects: 80
Study: 29698651

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (EX, n=216)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Non-exercise control (NON-EX, n=214)
Number of subjects: 430
Study: 27456718

Group type: EXPERIMENTAL
Intervention: Nooclerin (deanol aceglumate) for 2 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24791605

Group type: EXPERIMENTAL
Intervention: TF‐CBT plus evidence‐based engagement strategies
Number of subjects: 47

Group type: COMPARATOR
Intervention: TF‐CBT standard delivery
Number of subjects: 47
Study: 22372795

Group type: EXPERIMENTAL
Intervention: VECAM 40
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: VECAM 20
Number of subjects: 36

Group type: COMPARATOR
Intervention: OMP 20 mg
Number of subjects: 36
Study: 20928987

Group type: EXPERIMENTAL
Intervention: Sprinkles (micronutrient home supplementation with iron, vitamins A and C, folic acid, and zinc)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Standard treatment (liquid iron and vitamins A and D)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Sprinkles
Number of subjects: 621

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 621
Study: 17993007

Group type: EXPERIMENTAL
Intervention: Xinnaoxin capsules
Number of subjects: 118

Group type: COMPARATOR
Intervention: Nimodiping
Number of subjects: 118
Study: 15644006

Group type: EXPERIMENTAL
Intervention: 5 ml.h(‐1) ropivacaine 0.2% (study group, n = 21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 5 ml.h(‐1) saline (control group, n = 21)
Number of subjects: 42
Study: 12134102

Group type: EXPERIMENTAL
Intervention: Surgical closure of arteriovenous fistula
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (patent arteriovenous fistulas)
Number of subjects: 17
Study: 10900674

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogens
Number of subjects: 0

Group type: COMPARATOR
Intervention: HRT
Number of subjects: 0
Study: 8872628

Group type: EXPERIMENTAL
Intervention: 700-ml infusion of autologous erythrocytes (42% hematocrit)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Erythrocyte infusion
Number of subjects: 16
Study: 1732596

Group type: EXPERIMENTAL
Intervention: Intravesical epirubicin administration
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no epirubicin)
Number of subjects: 65
Study: 2857372

Group type: EXPERIMENTAL
Intervention: Home-care service for acute stroke patients
Number of subjects: 440

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 440
Study: 30705097

Group type: EXPERIMENTAL
Intervention: Pegylated-asparaginase, intravenously at a dose of 2,500 IU/m2 on days 12 and 26
Number of subjects: 736
Study: 28038881

Group type: EXPERIMENTAL
Intervention: Green tea extract plus diclofenac tablet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diclofenac tablet alone
Number of subjects: 50
Study: 27573032

Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 240

Group type: COMPARATOR
Intervention: Fluoroscopy-guided PCI (angiography-guided group)
Number of subjects: 240
Study: 23584930

Group type: EXPERIMENTAL
Intervention: Building on Family Strengths (BFS) curriculum
Number of subjects: 100
Study: 21696247

Group type: EXPERIMENTAL
Intervention: Aided paper and pen visual perception training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Computer-based visual perception training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 40
Study: 20538368

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Sedation (PCS)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Emergency Physician-Controlled Sedation (EPCS)
Number of subjects: 166
Study: 18164464

Group type: EXPERIMENTAL
Intervention: Needle acupuncture
Number of subjects: 0
Study: 15957997

Group type: EXPERIMENTAL
Intervention: MMP-9 activity in follicular fluid and culture media
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMP-2 activity in follicular fluid and culture media
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMP-9 expression in follicular fluid and culture media
Number of subjects: 0
Study: 12598214

Group type: EXPERIMENTAL
Intervention: At-home self-adjustment of CPAP (starting pressure based on prediction equation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: In-laboratory determined optimal pressure CPAP treatment
Number of subjects: 18
Study: 10413395

Group type: EXPERIMENTAL
Intervention: Family Practice
Number of subjects: 509

Group type: COMPARATOR
Intervention: General Internal Medicine
Number of subjects: 509
Study: 8585108

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg once daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2149053

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus teicoplanin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin
Number of subjects: 100
Study: 7452214

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31204681

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 0
Study: 28655025

Group type: EXPERIMENTAL
Intervention: CAM2038 24 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CAM2038 32 mg
Number of subjects: 47
Study: 25425205

Group type: EXPERIMENTAL
Intervention: Web-based family communication intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison families (control group)
Number of subjects: 0
Study: 22776322

Group type: EXPERIMENTAL
Intervention: Fissurectomy with anoplasty
Number of subjects: 264
Study: 20535518

Group type: EXPERIMENTAL
Intervention: SRP+NDL (SRP followed by Nd:YAG laser)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP (Scaling and Root Planing)
Number of subjects: 30
Study: 19785510

Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5 to 1.2 mg/kg/day, uptitrated after two weeks)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 16923216

Group type: EXPERIMENTAL
Intervention: Freshly chopped chilli blend (30 g/d; 55% cayenne chilli)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Bland diet (no chilli)
Number of subjects: 27
Study: 14990637

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 11333377

Group type: EXPERIMENTAL
Intervention: Preventative methods to reduce vertical transmission of HIV
Number of subjects: 0
Study: 9394683

Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy as fat)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-fat diet (20% of energy as fat)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 14
Study: 8030582

Group type: EXPERIMENTAL
Intervention: Mepiphylline (8 mg/kg/day divided in 3 doses for 10 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mepiphylline (8 mg/kg/day)
Number of subjects: 40
Study: 2542384

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 233825

Group type: EXPERIMENTAL
Intervention: Wheat fiber (36 g) added to diet for 3 weeks
Number of subjects: 6
Study: 31229695

Group type: EXPERIMENTAL
Intervention: Postcurriculum confidence score (after completing the curriculum)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Precurriculum confidence score (before completing the curriculum)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Comparison of precurriculum confidence between genders
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Postcurriculum confidence between genders
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Correlation between self-reported confidence and prior experience
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Correlation between self-reported confidence and performance
Number of subjects: 49
Study: 27187047

Group type: EXPERIMENTAL
Intervention: Closure of visceral and parietal peritoneums (group 2)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Closure of parietal peritoneum only (group 1)
Number of subjects: 133

Group type: COMPARATOR
Intervention: No closure of peritoneums (group 3)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Closure of visceral peritoneum only (group 4)
Number of subjects: 133
Study: 25589559

Group type: EXPERIMENTAL
Intervention: Saline flushing every 12 hours (group A)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Saline flushing every 24 hours (group B)
Number of subjects: 400
Study: 23861288

Group type: EXPERIMENTAL
Intervention: Cluster 1 (high optimism, low negative affect, pain vigilance, anger, and depression)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Cluster 2 (low positive affect, high somatic reactivity)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Cluster 3 (high pain vigilance, low optimism)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Cluster 4 (highest pain vigilance, reactivity, negative affect, anger, and depression)
Number of subjects: 194
Study: 21242173

Group type: EXPERIMENTAL
Intervention: Targeted recruitment strategies at seven institutions
Number of subjects: 18442

Group type: COMPARATOR
Intervention: Non-targeted recruitment at institutions without strategies
Number of subjects: 18442

Group type: EXPERIMENTAL
Intervention: Cost of targeted recruitment strategies
Number of subjects: 18442
Study: 19583677

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg (oral dose)
Number of subjects: 150
Study: 17033927

Group type: EXPERIMENTAL
Intervention: Exemestane therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen therapy
Number of subjects: 0
Study: 15534410

Group type: EXPERIMENTAL
Intervention: OP‐1 Putty (3.5 mg of OP‐1 per side)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Autogenous iliac crest bone graft
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both OP‐1 Putty and autograft
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: OP‐1 Putty
Number of subjects: 36
Study: 11535566

Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg once a day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Folic acid plus transdermal GTN
Number of subjects: 18

Group type: COMPARATOR
Intervention: Transdermal GTN plus placebo
Number of subjects: 18